All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Momelotinib Shows Real-World Improvements in Anemia, Symptoms, and Spleen Response in Myelofibrosis

December 12th 2024

Real-world treatment with momelotinib led to high transfusion independence rates among patients with JAK inhibitor–exposed and –naive myelofibrosis.

Zanidatamab Proves Efficacious in Pretreated Biliary Tract Cancer With Potential to Move to the Frontline

December 12th 2024

James J. Harding, MD, details the significance of the approval of zanidatamab and how the agent could fill unmet needs in biliary tract cancers.

Risk Management Measures Improved Safety, Prevention, and Management of Ponatinib-Associated AEs in CML and AML

December 11th 2024

Select safety measures have improved the prevention and management of risks associated with ponatinib in ALL and CML over 10 years.

Imlunestrant With or Without Abemaciclib Boosts PFS in ESR1+, ER+/HER2– Advanced Breast Cancer

December 11th 2024

Imlunestrant with or without abemaciclib improved PFS in select patients with ER-positive, HER2-negative advanced breast cancer after endocrine therapy.

Neoadjuvant Patritumab Deruxtecan ± Letrozole Shows Efficacy in High-Risk HR+/HER2– Breast Cancer

December 11th 2024

Neoadjuvant patritumab deruxtecan with or without letrozole produced pathologic complete responses in high-risk, HR-positive/HER2-negative breast cancer.

SHR-A1811 Shows Initial Antitumor Activity, Tolerability in HER2+ Breast Cancer

December 11th 2024

SHR-A1811 monotherapy demonstrated high clinical activity and was well tolerated in patients with HER2-positive breast cancer.

Adjuvant Olaparib Maintains iDFS Benefit in BRCA1/2+, HER2– Breast Cancer

December 11th 2024

Adjuvant olaparib maintained an efficacy benefit vs placebo in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast cancer.

Elacestrant Plus Abemaciclib Shows Efficacy in ER+/HER2– Advanced or Metastatic Breast Cancer

December 11th 2024

Elacestrant plus abemaciclib demonstrated clinically important efficacy in ER-positive/HER2-negative advanced or metastatic breast cancer.

Cilta-Cel Leads to 100% MRD-Negativity Rate in High-Risk Smoldering Multiple Myeloma

December 11th 2024

Cilta-cel without induction therapy in high-risk smoldering myeloma marked the first study of CAR T-cell therapy in a precursor cancer setting.

Risk-Reducing Surgery Improves Survival Outcomes in Younger BRCA+ Breast Cancer

December 11th 2024

Risk-reducing surgery improved survival outcomes in younger patients with breast cancer and a germline BRCA mutation.

T-DXd Improves PFS Irrespective of Time to Progression, Type of Endocrine Resistance in HER2-Low/-Ultralow Metastatic Breast Cancer

December 11th 2024

T-DXd improved PFS vs treatment of physician’s choice in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer.

Elacestrant Shows Tolerability in Combination With CDK4/6, PI3K Inhibitors in Advanced ER+ Breast Cancer

December 11th 2024

Elacestrant was partnered with multiple targeted agents across varying dose levels and schedules for patients with estrogen receptor–positive advanced breast cancer.

IO-202 Plus Azacitidine Elicits Responses in HMA-Naive Chronic Myelomonocytic Leukemia

December 11th 2024

IO-202 plus azacitidine elicited an ORR of 66.7% in patients with HMA-naive chronic myelomonocytic leukemia.

Potential Biomarkers Positively Prognosticate Outcomes With Pembrolizumab Plus Chemo in High-Risk TNBC

December 11th 2024

Pembrolizumab plus chemotherapy conferred an efficacy advantage over chemotherapy alone in high-risk TNBC subgroups defined by potential biomarkers.

Selinexor Plus Ruxolitinib Displays Activity in Ruxolitinib-Pretreated Myelofibrosis

December 11th 2024

Selinexor plus ruxolitinib showed activity in patients with myelofibrosis who were treated with ruxolitinib.

CAN-2409 Improves DFS in Intermediate/High-Risk Localized Prostate Cancer

December 11th 2024

CAN-2409 plus valacyclovir and radiation therapy significantly improved DFS in intermediate- to high-risk localized prostate cancer.

Anitocabtagene Autoleucel Elicits Deep Responses in Relapsed/Refractory Multiple Myeloma

December 11th 2024

Anito-cel elicited an ORR of 97% with acceptable safety in patients with relapsed or refractory multiple myeloma.

Dana-Farber Researchers to Present Findings at 2024 San Antonio Breast Cancer Symposium

December 11th 2024

Researchers from Dana-Farber Cancer Institute will present more than 30 research studies at the 47th annual San Antonio Breast Cancer Symposium

Lancet Breast Cancer Commission Report Addresses Challenges to Reduce Disease Burden

December 11th 2024

Reshma Jagsi, MD, DPhil, highlights key takeaways from the Lancet Breast Cancer Commission Report and the necessary steps forward emphasized in the report.

NFKB1 Haplotype Decreases Inflammation, Increases Response to Ropeginterferon Alfa-2b in PV and ET

December 11th 2024

NFKB1 rs230511 reduces inflammation and amplifies responses to ropeginterferon alfa-2b in polycythemia vera and essential thrombocythemia.